AB SCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.918 EUR | -2.14% |
|
-4.00% | -46.05% |
| Apr. 30 | AB Science S.A. Announces Slight Delay in Publication of Annual Financial Report 2023 | CI |
| Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| Sales 2023 * | 930K 996K | Sales 2024 * | 990K 1.06M | Capitalization | 97.95M 105M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -20.35M | Net income 2024 * | -18M -19.28M | EV / Sales 2023 * | 105 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 98.9 x |
| P/E ratio 2023 * |
-5.05
x | P/E ratio 2024 * |
-5.33
x | Employees | 89 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on AB Science
More press releases
More news
| 1 day | -2.14% | ||
| 1 week | -4.00% | ||
| Current month | -24.19% | ||
| 1 month | -24.19% | ||
| 3 months | -43.42% | ||
| 6 months | -16.24% | ||
| Current year | -46.05% |
1 week
1.88
2.01
1 month
1.882.53
Current year
1.554.47
1 year
1.556.26
3 years
1.5516.68
5 years
1.5521.75
10 years
1.5521.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
| Chief Tech/Sci/R&D Officer | - | 18-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
| Director/Board Member | 62 | 21-06-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 1.918 | -2.14% | 48,165 |
| 24-04-29 | 1.96 | +1.24% | 59,049 |
| 24-04-26 | 1.936 | +2.76% | 32,531 |
| 24-04-25 | 1.884 | -2.89% | 71,388 |
| 24-04-24 | 1.94 | -2.02% | 68,439 |
Real-time Euronext Paris, April 30, 2024 at 11:35 am EDT
More quotes
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.918
EUR
Average target price
6.895
EUR
Spread / Average Target
+259.49%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.05% | 105M | |
| +12.38% | 9B | |
| -12.75% | 4.96B | |
| +42.38% | 4.47B | |
| +5.23% | 3.9B | |
| +20.51% | 2.45B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B | |
| +3.94% | 1.65B |
- Stock Market
- Equities
- AB Stock
